Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00602563 · ClinicalTrials.gov registry record · NA
Attention Training for Generalized Anxiety Disorder
A NA study, sponsored by San Diego State University.
- Completed
- Registry status
- NA
- Development phase
- 193
- Enrollment target
NCT00602563: Completed NA study, sponsored by San Diego State University.
NCT00602563 is a NA study that has completed, run by San Diego State University. The registered enrollment target is 193 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00602563, a NA study, has completed, sponsored by San Diego State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 193 participants
- Enrollment target
Study Summary
Generalized Anxiety Disorder (GAD) has high prelevance (up to 8.5%; Roy-Byrne \& Wagner, 2004) and leads to functional impairment (Wittchen et al., 2002; Ballenger et al., 2001). Researchers have demonstrated a relationship between attention bias to threatening information and GAD. However, this knowledge has not yet been translated into effective treatments. The goal of this project is develop and test a new computerized treatment for Generalized Anxiety Disorder.
Interventions
- BEHAVIORAL AMP
- BEHAVIORAL Applied Relaxation (AR)
- BEHAVIORAL Clinical Monitoring (CM)
- BEHAVIORAL Combining the AMP and AR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 193 participants |
| Start Date | 2007-12 |
| Est. Completion | 2016-06 |
| Phase | NA |
What the finished NCT00602563 record still lists
NCT00602563 is an interventional study that assigns participants to a tested intervention. The registered 193 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 4 interventions - of which AMP is the first listed.
NCT00602563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00602563 about?
NCT00602563 is a clinical study titled "Attention Training for Generalized Anxiety Disorder". Generalized Anxiety Disorder (GAD) has high prelevance (up to 8.5%; Roy-Byrne \& Wagner, 2004) and leads to functional impairment (Wittchen et al., 2002; Ballenger et al., 2001). Researchers have demonstrated a relationship between attention bias to threatening information and GAD. However, this kno...
What is the current status of trial NCT00602563?
This trial is currently completed. It is a NA study. The enrollment target is 193 participants. The study started on 2007-12. Estimated completion is 2016-06.
What interventions are being tested in trial NCT00602563?
The interventions under investigation include: AMP (BEHAVIORAL), Applied Relaxation (AR) (BEHAVIORAL), Clinical Monitoring (CM) (BEHAVIORAL), Combining the AMP and AR (BEHAVIORAL).
Who is sponsoring clinical trial NCT00602563?
This trial is sponsored by San Diego State University, which has 118 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00602563's enrollment target sits among peer trials
193 569th of 2000 higher than 1,431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06226220 · 193 participants · NA
Percutaneous Nerve Evaluation Trial Time
- NCT03593759 · 194 participants · Phase 3
Cardiac Sarcoidosis Randomized Trial
- NCT05053152 · 194 participants · Phase 2
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
- NCT05156112 · 194 participants · NA
OSA PAP Treatment for Veterans With SUD and PTSD on Residential Treatment Unit
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia